Archive · 7 Nov 2025
Zydus Lifesciences Receives Tentative USFDA Approval for Olaparib Tablets
A company called Zydus Lifesciences is making a special medicine called Olaparib.
The medicine helps treat certain kinds of cancer like those in the ovaries, breasts, pancreas, and prostate.
It works for people who have specific changes in their genes, like the BRCA gene.
The US food and drug agency, called the USFDA, has given a preliminary thumbs-up for this medicine.
This is good news for the company and potentially for patients who need these treatments.
Zydus Lifesciences has received tentative approval from the USFDA for its Olaparib tablets.
Olaparib is used to treat specific types of ovarian, breast, pancreatic, and prostate cancers.
The drug is indicated for patients with genetic mutations, such as in the BRCA gene.
The approval is tentative, meaning further steps may be required.
Zydus Lifesciences' shares saw a slight increase on the BSE following the announcement.
- Who
- Zydus Lifesciences Ltd
- What
- Received tentative USFDA approval for Olaparib tablets
- When
- Not specified in the article
- Where
- United States (via USFDA approval)
- Why
- For the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers in patients with specific genetic mutations.
- Company
- Zydus Lifesciences Ltd
- Drug
- Olaparib Tablets
- Regulatory Approval
- Tentative USFDA Approval
- Stock Price (BSE)
- ₹943.80 (up 0.81%)